Trexquant Investment’s ADMA Biologics ADMA Stock Holding History

Trexquant Investment’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$138K	Sell	16,493 -1,128,348	-99%	-$10.3M	﹤0.01%	1817
2026 Q1	$10.3M	Buy	1,144,841 +774,021	+209%	+$12.2M	0.07%	372
2025 Q4	$6.76M	Sell	370,820 -46,547	-11%	-$784K	0.06%	454
2025 Q3	$6.12M	Sell	417,367 -78,211	-16%	-$1.34M	0.06%	469
2025 Q2	$9.02M	Buy	495,578 +466,671	+1,614%	+$9.52M	0.1%	280
2025 Q1	$574K	Sell	28,907 -5,527	-16%	-$95.6K	0.01%	1242
2024 Q4	$591K	Sell	34,434 -788,187	-96%	-$14.8M	0.01%	1240
2024 Q3	$16.4M	Buy	822,621 +311,979	+61%	+$4.85M	0.21%	119
2024 Q2	$5.71M	Buy	+510,642	New	+$4.28M	0.09%	367

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Trexquant Investment's ADMA Position: Q2 2026 in Review

Trexquant Investment reduced its ADMA Biologics (ADMA) stake by 99% in Q2 2026, selling an estimated $10.3M and leaving 16,493 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #1817.

Trexquant Investment first reported a position in ADMA in Q2 2024 and has held it in 9 quarters since. The position peaked at $16.4M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Trexquant Investment held 16,493 shares of ADMA Biologics worth $138K as of Q2 2026.
Trexquant Investment sold 1,128,348 ADMA Biologics shares in Q2 2026, an estimated $10.3M.
ADMA Biologics made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1817 holding.
Trexquant Investment first reported a position in ADMA Biologics in Q2 2024 and has held it in 9 quarters since.
Trexquant Investment's ADMA Biologics position peaked at $16.4M in Q3 2024.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.